Royalty Pharma plc
Board of Directors
Director data appears once the latest DEF 14A has been processed through the director-extraction pass.
Risk-factor diff
FY 2025 10-K vs. FY 2024Net-new paragraphs in the most recent 10-K's Item 1A. Companies rarely add risk language without a real reason — additions here are often a leading signal of management concerns.
“risks related to the growth and dynamics of the royalty market;”
“uncertainties related to acquiring interests in development-stage biopharmaceutical product candidates;”
“potential strategic acquisitions of operating biopharmaceutical companies;”
“our ability to generate increasing royalty receipts and to achieve attractive returns on our investments, including maintaining attractive internal rates of return and consistent returns on invested capital and returns on invested equity;”
“marketers of products that generate our royalties are outside of our control;”
Policies & disclosures
Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.